Humacyte, Inc.·4

Aug 29, 6:45 PM ET

Sander Dale A. 4

4 · Humacyte, Inc. · Filed Aug 29, 2024

Insider Transaction Report

Form 4
Period: 2024-08-27
Sander Dale A.
CFO and Chief Corp. Deve. Off.
Transactions
  • Exercise/Conversion

    Common Stock

    2024-08-27$2.56/sh+39,389$100,83641,389 total
  • Exercise/Conversion

    Stock Options (right to buy)

    2024-08-2739,3890 total
    Exercise: $2.56From: 2018-09-01Exp: 2025-09-01Common Stock (39,389 underlying)
  • Sale

    Common Stock

    2024-08-27$6.68/sh39,389$263,1192,000 total
Holdings
  • Common Stock

    (indirect: By Spouse)
    20,600
Footnotes (1)
  • [F1]The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $6.67 to $6.725. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Documents

1 file
  • 4
    wk-form4_1724971323.xmlPrimary

    FORM 4